Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Treasure Chest: Pharmaxis Back In Focus
Oct 15 2012
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. RBS analysts report improving momentum, and takeover speculation, for Pharmaxis.
Bionomics Acquisition A Plus
Sep 24 2012
Bionomics has moved into the cancer stem cell field through a US acquisition and on the news Bell Potter reiterates its Buy rating for the stock.
Phosphagenics Still Patched In
Sep 17 2012
Despite a drug crystallisation issue pushing back its testing timeline, Phosphagenics continues to offer upside through its drug patch delivery technology in the view of Bell Potter.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Sep 17 2012
Weekly update on recommendation, target price, and earnings forecast changes.
Neuren Adds Parkinson’s To Future Potential
Sep 11 2012
Bell Potter quite likes Neuren Pharmaceuticals because of progress with drugs for Traumatic Brain Injury and Autism Spectrum Disorders, plus developments in a Parkinson’s Disease compound offer.
Healthcare Sector Overbought?
Sep 11 2012
Analysts debate whether a good run for Australian healthcare defensives means time to take profits, or not.
The Short Report
Aug 29 2012
FNArena’s weekly update on short positions in the Australian share market.
CSL: True Blood But Fair Price?
Aug 23 2012
CSL delivered a solid result and further growth is expected but valuation is preventing a number of brokers from being more positive on the stock.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Aug 20 2012
Weekly update on recommendation, target price, and earnings forecast changes.
The Short Report
Aug 16 2012
FNArena’s weekly update on short positions in the Australian share market.
Analyse The Market From A Different Angle
Latest News
| 1 |
The Market In Numbers – 25 Jan 2025Jan 25 2025 - Australia |
| 2 |
ASX Winners And Losers Of Today – 24-01-25Jan 24 2025 - Daily Market Reports |
| 3 |
Next Week At A Glance – 27-31 Jan 2025Jan 24 2025 - Weekly Reports |
| 4 |
Chrysos Corp’s Road Paved With GoldJan 24 2025 - Small Caps |
| 5 |
Weekly Top Ten News Stories – 24 January 2025Jan 24 2025 - Weekly Reports |